A Prognostic Nomogram of Colon Cancer With Liver Metastasis: A Study of the US SEER Database and a Chinese Cohort

Chuan Liu, Ti Wen(Nankai University), Kanghui Xiang(First Hospital of China Medical University), Jiale Huang(Second Affiliated Hospital of Inner Mongolia Medical University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Chuan Hu(Qingdao University), Ying Chen(First Hospital of China Medical University), Jinglei Qu(First Hospital of China Medical University), Bowen Yang(Guangzhou University of Chinese Medicine), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Guangwei Zhang(First Hospital of China Medical University)
Frontiers in Oncology
February 26, 2021
10.3389/fonc.2021.591009
Cited by 24

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417